RENAL FAILURE IN FABRY DISEASE: POSSIBILITY OF RADICAL IMPROVEMENT OF PROGNOSIS


Cite item

Full Text

Abstract

Diagnosis and treatment of nephropathy in Fabry disease is discussed.

About the authors

V V Fomin

A A Pulin

V Fomin

A Pulin

References

  1. Hoffmann B. Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring. Orphanet J. Rare Dis. 2009; 4: 21
  2. Breunig F., Wanner C. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy. J. Nephrol. 2008; 21(1): 32-37
  3. Wozniak M.A., Kittner S.J., Tuhrim S. et al. Frequency of unrecognized fabry disease among young European-american and african-american men with first ischemic stroke. Stroke. 2010; 41(1): 78-81
  4. Hwu W.L., Chien Y.H., Lee N.C. et al. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). Hum. Mutat. 2009; 30(10): 1397-1405
  5. Thadhani R., Wolf M., West M.L. et al. Patients with Fabry disease on dialysis in the United States. Kidney Int 2002; 61: 249-255
  6. Tsakiris D., Simpson H.K., Jones E.H. et al. Rare diseases in renal replacement therapy in the ERA/EDTARegistry. Nephrol. Dial. Transplant. 1996; 11: 4-20
  7. Spada M., Pagliardini S., Yasuda M. et al. High incidence of later-onset fabry disease revealed by newborn screening. Am. J. Hum. Genet. 2006; 79(1): 31-40
  8. Kotanko P., Kramar R., Devrnja D. et al. Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J. Am. Soc. Nephrol. 2004;15(5): 1323-1329
  9. Nakao S., Kodama C., Takenaka T. et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int. 2003; 64(3): 801-807
  10. Ichinose M., Nakayama M., Ohashi T. et al. Significance of screening for Fabry disease among male dialysis patients. Clin. Exp. Nephrol. 2005; 9(3): 228-232
  11. Branton M.H., Schiffmann R., Sabnis S.G. et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002; 81: 122-138
  12. Eng C.M., Fletcher J., Wilcox W.R. et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J. Inherit. Metab. Dis. 2007; 30(2): 184-192
  13. Andrikos E., Iatrou C., Boletis J.N. et al. Evolution of Fabry disease in male patients: The Greek experience. Clin. Nephrol. 2010; 73(1): 58-63
  14. Grunfeld J., Lidove O., Joly D. et al. Renal disease in Fabry patients. J. Inherit. Metab. Dis. 2001; 24: 71-74
  15. Ortiz A., Oliviero J.P., Waldek S. et al. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol. Dial. Transplant. 2008; 23: 1600 - 1607
  16. Schiffmann R., Warnock D.G., Banikazemi M. et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol. Dial. Transplant. 2009; 24: 2102-2111
  17. Alroy J., Sabnis S., Kopp J.B. Renal pathology in Fabry disease. J. Am. Soc. Nephrol. 2002; 13: S134-S138
  18. Branton M.H., Schiffmann R., Sabnis S.G. et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore). 2002; 81(2): 122-138
  19. Fogo A.B., Bostad L., Svarstad E. et al.; all members of the International Study Group of Fabry Nephropathy (ISGFN). Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol. Dial. Transplant. 2009 Oct 15. [Epub ahead of print]
  20. Kampmann C., Linhart A., Baehner F. et al. Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int. J. Cardiol. 2008; 130(3): 367-373
  21. Kampmann C, Baehner F, Whybra C. et al. Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J. Am. Coll. Cardiol. 2002; 40(9): 1668-1674
  22. Barr C., Clarke J.T., Ntwari A. et al. Fabry disease urinary globotriaosylceramide/creatinine biomarker evaluation by liquid chromatography-tandem mass spectrometry in healthy infants from birth to 6 months. Mol. Genet. Metab. 2009; 97(4): 278-283
  23. Schiffmann R., Waldek S., Benigni A., Auray-Blais C. Biomarkers of Fabry disease nephropathy. Clin. J. Am. Soc. Nephrol. 2009 Nov 5 [Epub ahead of print].
  24. Eng C.M., Banikazemi M., Gordon R.E. et al. A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am. J. Hum. Genet. 2001;68: 711 - 722.
  25. Wilcox W.R., Banikazemi M., Guffon N., et al. Long term sa fety and efficacy of enzyme replacement therapy for Fabry disease. Am. J. Hum. Genet. 2004; 75: 65 - 74.
  26. Germain D.P., Waldek S., Banikazemi M. et al. Sustained, long-term renal stabilization after 54 moths of agalsidase b therapy in patients with Fabry disease. J. Am. Soc. Nephrol. 2007; 18: 1547-1557.
  27. Schaefer R.M., Tylki-Szymańska A., Hilz M.J. Enzyme replacemen t therapy for Fabry disease: a systematic review of available evidence. Drugs. 2009; 69(16): 2179-2205.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies